We are live on !
Find out more
Logos Global Management Portfolio holdings
AUM
$2.32B
Turnover
52.75%
1-Year Est. Return
536.01%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$320M
(+16%)
Cap. Flow
-$21M
Cap. Flow % of AUM
Cap. Flow %
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
48.35%
Holding
91
New
25
Increased
18
Reduced
19
Closed
23
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$95.5M |
| 2 |
Vera Therapeutics
VERA
|
+$82M |
| 3 |
Celldex Therapeutics
CLDX
|
+$53.3M |
| 4 |
Abivax
ABVX
|
+$39.5M |
| 5 |
Belite Bio
BLTE
|
+$38.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$190M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$84.4M |
| 3 |
Terns Pharmaceuticals
TERN
|
+$79.1M |
| 4 |
Cytokinetics
CYTK
|
+$57.7M |
| 5 |
United Therapeutics
UTHR
|
+$47.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Erasca
ERAS
$4.69B
| $223M | 9.58% |
12,150,000
+1,000,000
| +9% | +$14.3M |
2024 Q2
8 quarters
|
|
|
2
Abivax
ABVX
$7.65B
| $136M | 5.87% |
1,024,000
+349,000
| +52% | +$39.5M |
2025 Q3
3 quarters
|
|
|
3
Revolution Medicines
RVMD
$38.6B
| $131M | 5.64% |
700,000
-1,300,000
| -65% | -$190M |
2024 Q2
8 quarters
|
|
4
IDEAYA Biosciences
IDYA
$3.22B
| $112M | 4.81% |
3,000,000
-450,000
| -13% | -$13.8M |
2021 Q3
19 quarters
|
|
|
5
BioNTech
BNTX
$22.2B
| $94.4M | 4.07% |
+1,015,000
| New | +$95.5M |
2026 Q2
0 quarters
|
|
|
6
Vera Therapeutics
VERA
$2.05B
| $94.4M | 4.06% |
+2,200,000
| New | +$82M |
2026 Q2
0 quarters
|
|
7
Tango Therapeutics
TNGX
$3.83B
| $89.1M | 3.84% |
2,850,000
-150,000
| -5% | -$3.71M |
2025 Q3
3 quarters
|
|
8
Praxis Precision Medicines
PRAX
$6.94B
| $87M | 3.75% |
260,000
-25,000
| -9% | -$7.91M |
2025 Q2
4 quarters
|
|
|
9
Celldex Therapeutics
CLDX
$2.24B
| $78.1M | 3.36% |
2,100,000
+1,650,000
| +367% | +$53.3M |
2025 Q4
2 quarters
|
|
10
Dianthus Therapeutics
DNTH
$4.11B
| $78M | 3.36% |
800,000
+400,000
| +100% | +$34.9M |
2025 Q3
3 quarters
|
|
11
CG Oncology
CGON
$5.37B
| $71M | 3.06% |
1,000,000
+425,000
| +74% | +$27.8M |
2025 Q4
2 quarters
|
|
12
Disc Medicine
IRON
$2.98B
| $64M | 2.76% |
875,000
+315,000
| +56% | +$21.6M |
2024 Q2
8 quarters
|
|
13
Maze Therapeutics
MAZE
$1.57B
| $57.7M | 2.49% |
1,935,000
+700,000
| +57% | +$18.3M |
2025 Q1
5 quarters
|
|
14
Dyne Therapeutics
DYN
$2.8B
| $56.6M | 2.44% |
2,550,000
+1,150,000
| +82% | +$21.4M |
2020 Q3
23 quarters
|
|
15
MoonLake Immunotherapeutics
MLTX
$826M
| $52.1M | 2.24% |
2,675,000
+1,175,000
| +78% | +$21.3M |
2025 Q4
2 quarters
|
|
16
Ocular Therapeutix
OCUL
$1.41B
| $52M | 2.24% |
5,300,000
+1,450,000
| +38% | +$13.1M |
2023 Q4
10 quarters
|
|
17
Design Therapeutics
DSGN
$662M
| $43.4M | 1.87% |
3,000,000
+1,050,000
| +54% | +$13.1M |
2021 Q1
21 quarters
|
|
18
Olema Pharmaceuticals
OLMA
$620M
| $40.1M | 1.73% |
3,208,875
| – | – |
2020 Q4
22 quarters
|
|
|
19
Belite Bio
BLTE
$5.83B
| $38.5M | 1.66% |
+250,000
| New | +$38.3M |
2026 Q2
0 quarters
|
|
20
Achieve Life Sciences
ACHV
$687M
| $35.4M | 1.53% |
+5,425,000
| New | +$25.9M |
2026 Q2
0 quarters
|
|
21
Trevi Therapeutics
TRVI
$1.7B
| $35.1M | 1.51% |
1,880,000
-520,000
| -22% | -$7.56M |
2024 Q1
9 quarters
|
|
22
Cogent Biosciences
COGT
$5.14B
| $34.8M | 1.5% |
+900,000
| New | +$31.5M |
2026 Q2
0 quarters
|
|
23
ArriVent BioPharma
AVBP
$867M
| $34.7M | 1.5% |
1,000,000
+650,000
| +186% | +$19.2M |
2026 Q1
1 quarter
|
|
24
Crescent Biopharma
CBIO
$439M
| $34.2M | 1.47% |
1,900,000
+1,417,500
| +294% | +$27.7M |
2024 Q4
6 quarters
|
|
25
Compass Pathways
CMPS
$1.51B
| $31.8M | 1.37% |
+2,250,000
| New | +$22.8M |
2026 Q2
0 quarters
|
|
Similar funds
CWM
Logos Global Management's Q2 2026 Portfolio in Review
As of Q2 2026, Logos Global Management held 91 positions worth $2.32B, up 16% from $2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Logos Global Management's Q2 2026 filing shows 25 new, 18 increased, 19 reduced and 23 closed positions. Its largest new stake was BioNTech: 1,015,000 shares worth $94.4M. The largest sale was Revolution Medicines, an estimated $190M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.
- Logos Global Management's largest Q2 2026 buy was BioNTech: 1,015,000 shares worth $94.4M.
- Logos Global Management added most to Celldex Therapeutics in Q2 2026, an estimated $53.3M increase.
- Logos Global Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $190M.
- Logos Global Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $84.4M.
- Logos Global Management's ten largest holdings make up 48% of its $2.32B portfolio in Q2 2026.
- Logos Global Management opened 25 new positions and closed 23 in Q2 2026.
- Logos Global Management's portfolio value rose 16% quarter-over-quarter to $2.32B.
Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.